Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | peroxisome proliferator-activated receptor gamma | Starlite/ChEMBL | References |
Homo sapiens | peroxisome proliferator-activated receptor alpha | Starlite/ChEMBL | References |
Species | Potential target | Known druggable target/s | Ortholog Group |
---|---|---|---|
Schistosoma japonicum | IPR008946,Nuclear receptor, ligand-binding,domain-containing | Get druggable targets OG5_137778 | All targets in OG5_137778 |
Schistosoma japonicum | ko:K08701 nuclear receptor, subfamily 1, invertebrate, putative | Get druggable targets OG5_137778 | All targets in OG5_137778 |
Schistosoma mansoni | nuclear hormone receptor superfamily protein-related | Get druggable targets OG5_137778 | All targets in OG5_137778 |
Species | Potential target | Known druggable target | Length | Alignment span | Identity |
---|---|---|---|---|---|
Echinococcus granulosus | ecdysone induced protein 78C | peroxisome proliferator-activated receptor gamma | 477 aa | 447 aa | 28.2 % |
Brugia malayi | ecdysteroid receptor | peroxisome proliferator-activated receptor alpha | 468 aa | 397 aa | 25.4 % |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Loa Loa (eye worm) | hypothetical protein | 0.7332 | 1 | 0.5 |
Trypanosoma cruzi | malonyl-CoA decarboxylase, mitochondrial precursor, putative | 0.2881 | 0.3554 | 0.5 |
Schistosoma mansoni | nuclear hormone receptor superfamily protein-related | 0.0427 | 0 | 0.5 |
Wolbachia endosymbiont of Brugia malayi | malonyl-CoA decarboxylase | 0.7332 | 1 | 0.5 |
Leishmania major | malonyl-coa decarboxylase-like protein | 0.2881 | 0.3554 | 0.5 |
Trypanosoma brucei | malonyl-CoA decarboxylase, mitochondrial precursor, putative | 0.2881 | 0.3554 | 0.5 |
Trypanosoma cruzi | malonyl-CoA decarboxylase, mitochondrial precursor, putative | 0.2881 | 0.3554 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
%max (functional) | = 103 % | Agonist activity at human PPAR gamma in a HepG2 cells by PPAR-GAL4 transactivation assay relative to darglitazone | ChEMBL. | 16973358 |
%max (functional) | = 103 % | Agonist activity at human PPAR gamma in a HepG2 cells by PPAR-GAL4 transactivation assay relative to darglitazone | ChEMBL. | 16973358 |
%max (functional) | = 117 % | Agonist activity at human PPAR alpha in a HepG2 cells by PPAR-GAL4 transactivation assay relative to GW2331 | ChEMBL. | 16973358 |
%max (functional) | = 117 % | Agonist activity at human PPAR alpha in a HepG2 cells by PPAR-GAL4 transactivation assay relative to GW2331 | ChEMBL. | 16973358 |
EC50 (functional) | = 0.001 uM | Agonist activity at human PPAR gamma in a HepG2 cells by PPAR-GAL4 transactivation assay | ChEMBL. | 16973358 |
EC50 (functional) | = 0.001 uM | Agonist activity at human PPAR gamma in a HepG2 cells by PPAR-GAL4 transactivation assay | ChEMBL. | 16973358 |
EC50 (functional) | = 0.046 uM | Agonist activity at human PPAR alpha in a HepG2 cells by PPAR-GAL4 transactivation assay | ChEMBL. | 16973358 |
EC50 (functional) | = 0.046 uM | Agonist activity at human PPAR alpha in a HepG2 cells by PPAR-GAL4 transactivation assay | ChEMBL. | 16973358 |
EC50 (binding) | = 0.099 uM | Displacement of radiolabeled GW2331 from human PPAR alpha by SPA binding assay | ChEMBL. | 16973358 |
EC50 (binding) | = 0.099 uM | Displacement of radiolabeled GW2331 from human PPAR alpha by SPA binding assay | ChEMBL. | 16973358 |
Ki (binding) | = 0.011 uM | Displacement of radiolabeled darglitazone from human PPAR gamma by SPA binding assay | ChEMBL. | 16973358 |
Ki (binding) | = 0.011 uM | Displacement of radiolabeled darglitazone from human PPAR gamma by SPA binding assay | ChEMBL. | 16973358 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.